Identification of prognostic and predictive biomarkers of overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel, prednisone (DP) +/- bevacizumab (B) in CALGB 90401 (Alliance) Meeting Abstract
| Authors: | Halabi, S.; Yang, Q.; Starr, M. D.; Brady, J. C.; Armstrong, A. J.; George, D. J.; Kelly, W. K.; Beltran, H.; Morris, M. J.; Nixon, A. B. |
| Abstract Title: | Identification of prognostic and predictive biomarkers of overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel, prednisone (DP) +/- bevacizumab (B) in CALGB 90401 (Alliance) |
| Meeting Title: | 2021 Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2021 Feb 11-13 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-02-20 |
| Language: | English |
| ACCESSION: | WOS:000636801500199 |
| DOI: | 10.1200/JCO.2021.39.6_suppl.154 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 154 -- Source: Wos |
